| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/07/2011 | WO2011041542A2 Herbal pain killer compositions |
| 04/07/2011 | WO2011041512A2 Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases |
| 04/07/2011 | WO2011041509A1 Orally administered corticosteroid compositions |
| 04/07/2011 | WO2011041470A2 Sustained-release opiate and opiate derivative compositions |
| 04/07/2011 | WO2011041462A2 Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| 04/07/2011 | WO2011041461A2 Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| 04/07/2011 | WO2011041451A2 Smoking cessation with body weight maintenance and nutritional supplement |
| 04/07/2011 | WO2011041414A1 Methods and compositions for deterring abuse |
| 04/07/2011 | WO2011041399A2 Pi3k (delta) selective inhibitors |
| 04/07/2011 | WO2011041385A2 Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis |
| 04/07/2011 | WO2011041384A2 Pectin compounds, methods of using pectin compounds, and methods of controlling water solubility |
| 04/07/2011 | WO2011041373A1 Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| 04/07/2011 | WO2011041369A1 Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same |
| 04/07/2011 | WO2011041311A2 Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods |
| 04/07/2011 | WO2011041309A1 Methods and compositions for treatment of ocular fibrosis |
| 04/07/2011 | WO2011041304A2 Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase |
| 04/07/2011 | WO2011041300A1 Reduced-odor polyol composition and method of producing same |
| 04/07/2011 | WO2011041293A1 Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| 04/07/2011 | WO2011041287A1 Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors |
| 04/07/2011 | WO2011041284A1 Process for preparing biphenyl imidazole compounds |
| 04/07/2011 | WO2011041217A1 The use of a par-1 antagonist in combination with a p2y12adp receptor antagonist for inhibition of thrombosis |
| 04/07/2011 | WO2011041198A1 Substituted imidazole derivatives for treatment of alzheimers disease |
| 04/07/2011 | WO2011041181A1 Reversed biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
| 04/07/2011 | WO2011041157A1 Crystalline hydrochloride salts of c-met kinase inhibitors |
| 04/07/2011 | WO2011041154A1 Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| 04/07/2011 | WO2011041146A2 Dosage regimen of an s1p receptor modulator |
| 04/07/2011 | WO2011041075A1 Eczema treatment with vitamin d and analogs thereof method, composition and cream |
| 04/07/2011 | WO2011040954A2 Tp53 gene expression and uses thereof |
| 04/07/2011 | WO2011040894A1 Topical compositions of opioid antagonists and methods for treating skin conditions therewith |
| 04/07/2011 | WO2011040651A1 Therapeutic agent for atopic dermatitis |
| 04/07/2011 | WO2011040613A1 Therapeutic agent for tumor |
| 04/07/2011 | WO2011040600A1 NOVEL ANTIBACTERIAL AGENT TARGETING RESPONSE REGULATOR WaIR(YycF) |
| 04/07/2011 | WO2011040597A1 Pharmaceutical composition containing medicament-containing fine particles and method for producing same |
| 04/07/2011 | WO2011040572A1 Ophthalmic composition |
| 04/07/2011 | WO2011040510A1 Indazole analogue |
| 04/07/2011 | WO2011040509A1 2,3-dihydro-1h-indene-2-ylurea derivative and pharmaceutical application of same |
| 04/07/2011 | WO2011040503A1 Method for recovery of sensitivity to anti-cancer agents in cancer cell that acquires resistance to anti-cancer agents |
| 04/07/2011 | WO2011040496A1 Heparanase activity inhibitor |
| 04/07/2011 | WO2011040495A1 Heparanase-activity inhibitor, wrinkle ameliorating agent containing same, and pharmaceutical composition |
| 04/07/2011 | WO2011040449A1 Novel phenol derivative |
| 04/07/2011 | WO2011040432A1 Eye wash agent |
| 04/07/2011 | WO2011040421A1 Screening method |
| 04/07/2011 | WO2011040386A1 Novel crystal of piperacillin sodium monohydrate |
| 04/07/2011 | WO2011040363A1 Collagen production accelerating composition |
| 04/07/2011 | WO2011040342A1 Agent for inhibiting decrease of visceral fat in patient with parkinson's disease |
| 04/07/2011 | WO2011040220A1 Composition for treatment of pancreatic cancer |
| 04/07/2011 | WO2011040212A1 Therapeutic agent for brain tumor |
| 04/07/2011 | WO2011040195A1 Unpleasant taste-masking particles and an oral preparation containing same |
| 04/07/2011 | WO2011040185A1 Oral composition for reducing skin roughness |
| 04/07/2011 | WO2011040166A1 Oral composition for reducing wrinkle formation |
| 04/07/2011 | WO2011040141A1 Composition containing fat-soluble vitamin |
| 04/07/2011 | WO2011040082A1 Laminin-332 production accelerating composition |
| 04/07/2011 | WO2011040071A1 Antioxidant composition |
| 04/07/2011 | WO2011040070A1 Oral composition for alleviation of ultraviolet radiation-induced damage |
| 04/07/2011 | WO2011040004A1 Novel phenylpyridine derivative and medicinal agent comprising same |
| 04/07/2011 | WO2011039999A1 Composition having lipolysis-promoting effect |
| 04/07/2011 | WO2011039746A1 Amide derivatives of valproic acid and uses thereof |
| 04/07/2011 | WO2011039735A2 Compounds with ddx3 inhibitory activity and uses thereof |
| 04/07/2011 | WO2011039721A1 New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| 04/07/2011 | WO2011039686A1 Latrepirdine oral sustained release dosage forms |
| 04/07/2011 | WO2011039648A1 Methods of administration and treatment |
| 04/07/2011 | WO2011039638A2 Topical tetracycline compositions |
| 04/07/2011 | WO2011039528A1 2-pyridone compounds used as inhibitors of neutrophil elastase |
| 04/07/2011 | WO2011039527A1 Formulations for c-met kinase inhibitors |
| 04/07/2011 | WO2011039403A1 Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases |
| 04/07/2011 | WO2011039379A1 Cooperative conveyance of basic active principles by amphiphilic acid molecules |
| 04/07/2011 | WO2011039367A2 Therapeutic uses of pharmaceutical compositions |
| 04/07/2011 | WO2011039365A1 Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles |
| 04/07/2011 | WO2011039358A1 Pyrazole derivatives which modulate stearoyl-coa desaturase |
| 04/07/2011 | WO2011039353A1 New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
| 04/07/2011 | WO2011039344A1 Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
| 04/07/2011 | WO2011039338A2 Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
| 04/07/2011 | WO2011039337A1 Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| 04/07/2011 | WO2011039282A1 Means and methods for treating ischemic conditions |
| 04/07/2011 | WO2011039221A2 Phosphoramidate derivatives of nucleosides |
| 04/07/2011 | WO2011039175A1 Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus |
| 04/07/2011 | WO2011039130A1 New benzimidazole derivatives and their use as fxr agonists |
| 04/07/2011 | WO2011039107A1 Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| 04/07/2011 | WO2011038933A2 Anti-hsv antibody |
| 04/07/2011 | WO2011038924A2 Treatment of disease with proteasome inhibitors |
| 04/07/2011 | WO2011038898A1 Arabinogalactan for enhancing the adaptive immune response |
| 04/07/2011 | WO2011038872A1 Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate |
| 04/07/2011 | WO2011038700A1 Inhibitors of fam3b gene, inhibitor compositions, inhibiting methods and applications of inhibitors in preparing pharmaceuticals |
| 04/07/2011 | WO2011038683A1 Controlled release formulation of carvedilol |
| 04/07/2011 | WO2011038662A1 Compounds as trpv1 blockers, pharmaceutical compositions and medical uses thereof |
| 04/07/2011 | WO2011038579A1 Compounds and compositions as protein kinase inhibitors |
| 04/07/2011 | WO2011038574A1 Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders |
| 04/07/2011 | WO2011038572A1 Novel compounds |
| 04/07/2011 | WO2011038537A1 Methods and kits for the prediction, prevention and treatment of septicemia and septic shock |
| 04/07/2011 | WO2011038485A1 Crosslinked hydrogels and related method of preparation |
| 04/07/2011 | WO2011038467A1 Method of treatment of philadelphia chromosome positive leukaemia |
| 04/07/2011 | WO2011038446A1 Cosmetic foam |
| 04/07/2011 | WO2011020001A3 Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases |
| 04/07/2011 | WO2011018801A3 Solid oral dosage form of ziprasidone |
| 04/07/2011 | WO2011018653A3 Treatment of viral infections |
| 04/07/2011 | WO2011015522A3 Process for the manufacture of pharmaceutically active compounds |
| 04/07/2011 | WO2011014766A3 Crystallization method and bioavailability |
| 04/07/2011 | WO2011000945A9 Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns |
| 04/07/2011 | WO2010151664A3 Compositions and methods for treating cancer and modulating stress granule formation |
| 04/07/2011 | WO2010149172A3 SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |